Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Biocartis Group NV    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Press news Biocartis Group NV: Invitation to the Extraordinary Shareholders' Meeting

09/04/2020 | 01:01am EST

PRESS RELEASE: REGULATED INFORMATION
4 September 2020, 07:00 CEST
                                                                                                           

Invitation to the Extraordinary Shareholders’ Meeting

Mechelen, Belgium, 4 September 2020Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to a new extraordinary shareholders' meeting that will be held on Friday 25 September 2020 at 9:00 a.m. CEST, at the offices of the Company at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium. The legally required quorum to validly deliberate and vote on the agenda items of the extraordinary shareholders' meeting held on 2 September 2020 was not reached.

In light of the COVID-19 pandemic, it is currently envisaged that the measures imposed by the Belgian government to deal with this pandemic, such as the obligation to guarantee a distance of 1.5 meters between each person, may still be in effect as of 25 September 2020, date of the Company's extraordinary shareholders' meeting. These measures are in the interest of the health of individual securities holders, as well as of the employees of the Company and others who are responsible for organizing the shareholders' meeting. It can also not be excluded that the Belgian government will again impose additional measures. We will monitor the situation closely and will disclose all relevant information and measures that have an impact on the shareholders' meeting on the Biocartis website.

In view hereof, the Company recommends that the shareholders that wish to participate in the extraordinary shareholders' meeting make use, as much as practically possible, of the right to vote through voting by mail or by proxy to the chairman of the Board of Directors. Furthermore, it is recommended that holders of securities that wish to exercise their right to ask questions regarding the items on the agenda of the extraordinary shareholders' meeting do so in writing. The modalities of the aforementioned means of participation in the extraordinary shareholders' meeting are set out in the convening notice and in the relevant forms for voting by mail or by proxy.

In order to be admitted to the extraordinary shareholders’ meeting, the holders of securities issued by the Company must comply with Article 7:134 of the Belgian Code of Companies and Associations and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the shareholders’ meetings can be consulted on the Company’s website.

--- END ---

More information:
Renate Degrave
Head of Corporate Communications & Investor Relations Biocartis
e-mail   rdegrave@biocartis.com
tel         +32 15 631 729
mobile   +32 471 53 60 64

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

© OMX, source OMX

All news about BIOCARTIS GROUP NV
11/24BIOCARTIS : Disclosure of a transparency notification
PU
11/24PRESS NEWS BIOCARTIS GROUP NV - REGU : Disclosure of a transparency notification
AQ
11/17BIOCARTIS : Announces Publication of Large Multi-Center Comparison Study with Id..
PU
11/17PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces Publication of Large Multi-C..
AQ
11/16BIOCARTIS : Announces Ten Idylla™ Studies to be Published at Virtual AMP (..
PU
11/16PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces Ten Idylla™ Studies t..
AQ
11/12BIOCARTIS : Q3 2020 business update
PU
11/12PRESS NEWS BIOCARTIS GROUP NV : Biocartis q3 2020 business update
AQ
11/12BIOCARTIS GROUP NV : 3rd quarter earnings
CO
11/10PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces CE-marking of its Fully Auto..
AQ
More news
Financials
Sales 2020 44,8 M 54,3 M 54,3 M
Net income 2020 -57,7 M -69,9 M -69,9 M
Net Debt 2020 113 M 137 M 137 M
P/E ratio 2020 -4,42x
Yield 2020 -
Capitalization 271 M 328 M 329 M
EV / Sales 2020 8,58x
EV / Sales 2021 7,33x
Nbr of Employees 499
Free-Float 83,3%
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 7,75 €
Last Close Price 4,82 €
Spread / Highest target 86,9%
Spread / Average Target 61,0%
Spread / Lowest Target 40,2%
EPS Revisions
Managers
NameTitle
Herman Verrelst Chief Executive Officer & Executive Director
Christian Reinaudo Independent Chairman
Piet Houwen Chief Operating Officer
Jean-Marc Roelandt Chief Financial Officer
Benoit Devogelaere Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOCARTIS GROUP NV-15.82%328
MASIMO CORPORATION61.03%14 013
NOVOCURE LIMITED54.53%13 256
ASAHI INTECC CO., LTD.14.06%9 100
PENUMBRA, INC.24.94%7 453
GETINGE AB4.25%5 809